Background-Three-fourths of cardiac arrest survivors die before hospital discharge or suffer significant neurological injury. Except for therapeutic hypothermia and revascularization, no novel therapies have been developed that improve survival or cardiac and neurological function after resuscitation. Nitrite (NO 2 Ϫ ) increases cellular resilience to focal ischemia/reperfusion injury in multiple organs. We hypothesized that nitrite therapy may improve outcomes after the unique global ischemia/reperfusion insult of cardiopulmonary arrest. Methods and Results-We developed a mouse model of cardiac arrest characterized by 12 minutes of normothermic asystole and a high cardiopulmonary resuscitation rate. In this model, global ischemia and cardiopulmonary resuscitation were associated with blood and organ nitrite depletion, reversible myocardial dysfunction, impaired alveolar gas exchange, neurological injury, and an Ϸ50% mortality. A single low dose of intravenous nitrite (50 nmolϭ1.85 mol/kgϭ0.13 mg/kg) compared with blinded saline placebo given at cardiopulmonary resuscitation initiation with epinephrine improved cardiac function, survival, and neurological outcomes. From a mechanistic standpoint, nitrite treatment restored intracardiac nitrite and increased S-nitrosothiol levels, decreased pathological cardiac mitochondrial oxygen consumption resulting from reactive oxygen species formation, and prevented oxidative enzymatic injury via reversible specific inhibition of respiratory chain complex I. Conclusion-Nitrite therapy after resuscitation from 12 minutes of asystole rapidly and reversibly modulated mitochondrial reactive oxygen species generation during early reperfusion, limiting acute cardiac dysfunction, death, and neurological impairment in survivors. (Circulation. 2009;120:897-905.)
including rodent heart, 8 brain, 9 liver, 8 and kidney; canine heart 10 ; and primate brain. 11 Systemic nitrite reduction by ceruloplasmin knockout 12 or dietary nitrate/nitrite elimination 13 increased infarction volume in the liver and heart after experimental ischemia. These studies indicate that physiological systemic nitrite levels modulate host resilience to ischemia. The established safety of human and animal nitrite dosing 14 and its potent effects in limiting major organ injury suggest that nitrite represents an ideal therapy for cardiac arrest.
Cardiac arrest results in global multiorgan ischemic injury associated with significant morbidity and mortality. 15, 16 More than 70% of those resuscitated die before hospital discharge. 15, 16 Except for the selective application of hypothermia and revascularization, no novel postresuscitation therapies have been developed that improve survival or cardiac and neurological function. 15 We explored nitrite therapy in a mouse model of cardiac arrest. Here, we provide evidence that nitrite therapy improves cardiac function, survival, and neurological function in survivors. Mechanistically, we show that nitrite specifically and reversibly inhibits cardiac complex I, limiting oxidative reperfusion injury. The ease of delivery, established human safety, and efficacy of nitrite in murine cardiac arrest suggest its promise as a novel therapy after cardiac arrest.
Methods

Mouse Cardiac Arrest Model
In initial model building, we adapted mouse cardiac arrest models from prior reports 17, 18 with the goal of nearly 100% resuscitation and 50% 24-hour mortality. To modulate mortality, we extended asystolic time from 8 to 12 minutes and added epinephrine to increase return of spontaneous circulation (ROSC). Seven-to 12-week-old (24 to 30 g) C57BL/6 male mice were used as approved by the National Institutes of Health Institutional Animal Care and Use Committee. Anesthesia consisting of intraperitoneal ketamine and xylazine (100 and 15 mg/kg, respectively) preceded surgical preparation, including orotracheal intubation and placement of right carotid and jugular catheters. Ventilation (ASV, Harvard Instruments, Cambridge, Mass) for 10 minutes (minimum) at a rate of 110 bpm and a volume of 15 mL/kg preceded cardiac arrest and produced normal blood gases (Table 1) . ECG, arterial blood pressure, exhaled carbon dioxide, and rectal temperature were recorded at baseline and during 60 minutes after resuscitation (Powerlab, ADInstruments, Colorado Springs, Colo). Asystole was induced by 100-L potassium chloride (0.09 g/kg; minimum, 2.5% [wt/vol]) intravenous bolus, and temperature was maintained at 36.5°C for 12 minutes. Cardiopulmonary resuscitation (CPR) was performed with rapid (375 to 425) finger compressions, resumption of mechanical ventilation (25% tidal volume increase), and 10 g intravenous epinephrine (500 L) before CPR and 2 g (100 L) 1 minute after CPR. Animals received either 50 nmol (1.85 mol/kgϭ0.13 mg/kg) sodium nitrite (in 0.9% saline) or saline placebo intravenously in a randomized, blinded fashion at CPR initiation. This dose and timing of delivery were based on prior work. 8 To minimize variability, we paired inbred animals to nitrite or placebo on the basis of similar weight, sex, age, delivery date, and when possible, holding cage. Pairing appeared effective (Table 2) . Postresuscitation care was uniform between groups. A model summary is provided in Figure 1 . Sham control animals received anesthesia, surgery, and ventilation but no cardiac arrest and the same postresuscitation care until the similarly timed end point. Shams were drawn from the same batch as experimental animals.
Blood Gases and Blood/Tissue Nitrite Levels
Carotid arterial blood was obtained in a heparinized syringe either 55 minutes after anesthesia (sham) or 5 minutes after CPR. Blood was used for blood gas analysis (Nova Biomedical, Waltham, Mass), mixed 4:1 with nitrite preservation solution, 4 or centrifuged to isolate plasma for nitrite measurements. Animals were perfused 19 with tissue nitrite preservation solution (1 mmol/L KCN, 0.2% NP-40, 0.8 mmol/L ferricyanide, 0.5 mmol/L NEM, 100 mol/L DTPA), and brains were homogenized for nitrite measurements. Snap-frozen hearts obtained 15 minutes after CPR were sectioned at Ϫ20°C, placed in ice-cold nitrite preservation solution, and homogenized for nitrite measurements. All nitrite measurements were determined by tri-iodide-based gas-phase reductive chemiluminescence with an NO analyzer (GE Analytic, Boulder, Colo) as described previously, 20, 21 and tissue levels were normalized to protein content (BCA Protein Assay, Pierce, Rockford, Ill).
Left Ventricular Echocardiography
Animals had line removal, wound closure, and chest hair removal before transportation for echocardiogram 60 minutes after CPR or sham surgery. Animals were secured to the Vevo 770 (VisualSonics, Toronto, Ontario, Canada) platform, and temperature and ECG were monitored (temperature maintained at Ͼ35°C, heart rate at Ͼ300 bpm; supplemental oxygen delivered via nose cone). Parasternal long-axis 2-dimensional images of the left ventricle (LV) were obtained with the RMV707B scan head 75 to 90 minutes after CPR. M-mode images were used to measure end-systolic and end-diastolic ventricular size, and fractional shortening and ejection fraction (EF) were calculated with the manufacturer's software (version 2.3.0).
Cardiac Magnetic Resonance Imaging
Anesthetized animals (1% to 1.5% isoflurane) underwent magnetic resonance imaging (MRI) 24 hours after CPR or sham surgery. Magnetic resonance imaging experiments were carried out in a 7.0-T, 16-cm horizontal Bruker MR imaging system (Bruker, Billerica, Mass) with Bruker ParaVision 3.0.2 software. Magnevist (Bayer HealthCare, Montville, NJ) diluted 1:10 with sterile 0.9% saline was administered subcutaneously at a dose of 0.3 mmol/kg. Six short-axis slices were used to determine EF and ventricular volumes using CAAS-MRV-FARM software (Pie Medical Imaging, Maastricht, the Netherlands).
Histology
Mice were transcardiac perfused with saline followed by 10% buffered formalin. 19 Brains were removed, further fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Seven serial high-powered (ϫ400) fields of bilateral CA1 at Bregma Ϫ1.5 mm were examined, and live and dead cells were counted and normalized to hippocampal length as described elsewhere. 17 
Mitochondria Isolation
Heart mitochondrial isolation was performed by differential centrifugation as described elsewhere, 22 and protein concentration was determined. Fresh mitochondria were used for respirometry, ROS, and ATP generation assays, and aliquots were stored at Ϫ80°C for subsequent complex I activity assays as described previously. 23 
Aconitase Activity
Hearts snap-frozen 15 minutes after CPR or sham surgery were homogenized in the manufacturer's commercial buffer, and lysates were prepared by 3 freeze/thaw cycles. Aconitase activity was determined by spectrophotometric (340 nm) monitoring of NADPH formation with the Bioxytech Aconitase-340 kit (Oxis Research, Beverly Hills, Calif).
Statistical Analysis
Data are given as meanϮSEM; analyses were performed with GraphPad Prism 5 (La Jolla, Calif). Continuous data were compared between 3 groups with 1-way ANOVA with posthoc Bonferroni adjustment and between 2 groups with paired Student t test for variables that are normally distributed, Wilcoxon for variables that are not normally distributed, and repeated-measures ANOVA for variables measured at multiple time points from the same subjects. Mitochondrial experiments were performed as multiple paired experiments at discrete times and therefore analyzed at each time using a paired t test. Mortality was assessed by Kaplan-Meier survival analysis (log-rank test). A 2-tailed value of PϽ0.05 was considered statistically significant. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Cardiac Arrest Physiological Effects
Cardiac arrest resulted in metabolic (lactic) and respiratory acidosis and oxygen depletion (Table 1) . Ischemic times and resuscitation rates were similar between groups (Table 2) .
Cardiac arrest led to transient hyperemia soon after resuscitation ( Figure 1B) as described by others. 17 One hour after resuscitation, placebo-treated mice exhibited signs of myocardial depression based on decreased blood pressure, increased tachycardia ( Figure 1C) , and decreased EFs ( Figure  1D ) compared with prearrest baseline. Twenty-four hours later, LVEF had normalized but right ventricular (RV) failure remained as indicated by RV dilation and diminished RVEF ( Figure 1E ). Because right-sided pressures were not assessed, it is unclear whether this was due to pulmonary hypertension or loss of RV contractility.
Cardiac Arrest Depletes Systemic Nitrite, Which Is Reversed by Intravenous Therapy
Nitrite is reduced to NO and NO-modified proteins during focal ischemia in rodents. 13, 24 We tested the hypothesis that basal systemic levels of nitrite would be reduced by ischemic consumption during cardiac arrest and intravenous nitrite could restore levels (Figure 2A) . In placebo-treated mice, ischemia depleted whole-blood nitrite levels (0.64Ϯ0.05 mol/L) and nitrite therapy restored these levels (1.01Ϯ0.06 mol/L) to near baseline (1.15Ϯ0.10 mol/L). These findings were mirrored in plasma ( Figure 2B ) and heart ( Figure  2E ), and a similar trend was noted in brain ( Figure 2C ). S-nitrosation of the cardiomyocyte L-type calcium channel 25 and mitochondrial complex I 23,25 is a protective posttranslational modification resulting from nitrite therapy or ischemic Whole-blood (A) and plasma (B) nitrite levels (nϭ6) measured after 12 minutes of global ischemia and 5 minutes of reperfusion are depleted in placebo vs sham, and nitrite therapy increases levels with similar trends in brain (C). D, A sample reductive chemiluminescence tracing measuring nitrite in heart 15 minutes after CPR. Peaks represent total tissue nitrite (first peak), S-nitrosothiols (second peak), and the mercury stable fraction (third peak; not visible). E, Ischemia depletes heart nitrite in placebos, and nitrite therapy significantly increases total levels and S-nitrosothiols (F; nϭ7 preconditioning. We found that total S-nitrosothiol-modified protein concentration ( Figure 2F ) did not change with ischemia but nitrite therapy significantly increased these levels (PϽ0.05).
Nitrite Repletion Improves Cardiac Function
Increased systemic nitrite in treated mice was associated with improved cardiac function. Just before CPR, animals exhibited similar vascular loading based on identical asystolic pressures ( Figure 3A and 3C) compared with placebotreated mice (43.5Ϯ2.9%; Pϭ0.007). Heart rate and blood pressure were similar between treatment groups throughout post-ROSC monitoring (data not shown; PϾ0.2). Given similar baseline volume loading before CPR and similar mean blood pressures before imaging, the LVEF improvements likely indicate improved LV contractility. RVEF measured by magnetic resonance imaging ( Figure 3B and 3D) 24 hours after CPR was significantly better in nitrite-treated mice (54.7Ϯ1.3%) than in placebo-treated mice (42.8Ϯ1.7%; PϽ0.001). Consistent with improved pulmonary perfusion, gas exchange 5 minutes after CPR was improved with nitrite therapy compared with placebo (Table 1) .
Nitrite Repletion Improves Survival and Survivor Neurological Function
Death after ROSC occurred 1 to 6 hours after CPR; after that point, all animals survived until the subsequent day ( Figure  4 ). We observed bradycardia and hypotension progressing to asystole in mice dying early (while monitored), consistent with death from postischemic myocardial stunning and heart Because a third of cardiac arrest survivors have neurological disability, we blindly assigned neurological scores 18 to all mouse pairs surviving 1 day (nϭ11; Figure 5A ). The median score for nitrite-treated mice 11 was significantly better than for placebo-treated mice (9; Pϭ0.020). In all pairs, placebotreated mice exhibited impairment that was equal to or more severe than nitrite-treated mice. We measured rectal temperature 22 hours after resuscitation ( Figure 5B ) because rodent hypothermia correlates with severity of injury. 26 Nitritetreated mice had better thermoregulation (34.9Ϯ0.4°C) than placebo-treated mice (32.4Ϯ0.9°C; Pϭ0.013). Sham surgery did not impair neurological scores (all 12) or thermoregulation (36.5Ϯ0.5°C). Hippocampal CA1, known to be selectively vulnerable to global ischemia, showed no histological injury at 24 hours, consistent with prior observations. 27 Seventy-two-hour survival experiments were therefore performed (nϭ3), demonstrating increased CA1 neuronal injury in placebo-treated compared with nitrite-treated mice ( Figure  5C and 5D).
Nitrite Specifically and Reversibly Inhibits Complex I
On the basis of prior observations, 23, 28 we hypothesized that nitrite therapy in vivo would transiently S-nitrosate and inhibit mitochondrial complex I, resulting in a decrease in reperfusion ROS. Heart mitochondria from mice treated with nitrite isolated 5, 15, and 60 minutes after CPR exhibited reduced state 3 respiration using the complex I substrate pyruvate ( Figure 6A ) at 5 and 15 minutes but not 1 hour compared with placebo. Nitrite therapy did not reduce electron transport efficiency based on respiratory control ratio (5 minutes, 9.5Ϯ1.7; 60 minutes, 13.9Ϯ4.4), which was similar to the placebo-treated group (5 minutes, 7.5Ϯ1.0; 60 minutes, 10.4Ϯ4.6). Complex II (succinate) -dependent state 3 respiration was similar at all times ( Figure 6B ) and did not change with rotenone inhibition (data not shown), indicating the complex I specificity of nitrite. Complex I activity measured by NADH oxidation at 5 and 60 minutes confirmed the respirometry findings ( Figure 6C ). Using pyruvate as substrate, we consistently found increased oxygen consumption by placebo-treated postarrest mitochondria compared with prearrest despite reduced complex I (NADH consumption). This suggests pathological oxygen consumption to form ROS rather than to produce energy. Complex I inhibition was reversed 60 minutes after CPR as measured by respirometry ( Figure 6A ) and NADH oxidation ( Figure 6C ). ATP generation was similar between 60 minutes postarrest nitritetreated mice (58.1Ϯ8.1 nmol · min Ϫ1 · mg Ϫ1 protein) and placebo-treated mice (57.1Ϯ8.7 nmol · min Ϫ1 · mg Ϫ1 ) and prearrest mice (65.1Ϯ4.3 nmol · min Ϫ1 · mg Ϫ1 ), indicating no persistent functional complex I inhibition.
Nitrite Limits Reperfusion ROS Generation
Consistent with pathological oxygen conversion to ROS, peroxide generation by respiring mitochondria (pyruvate substrate) 5 and 15 minutes after CPR exceeded that of prearrest mice but normalized by 1 hour (Figure 7A ). Cardiac mitochondria from nitrite-treated mice had significantly less peak (5 minutes after CPR) ROS production (14.0Ϯ3.2 pmol · min Ϫ1 · mg Ϫ1 protein) compared with placebo-treated mice (26.6Ϯ4.4 pmol · min Ϫ1 · mg Ϫ1 ; PϽ0.01). The abundant mitochondrial enzyme aconitase is susceptible to oxidative modification, which decreases its activity, and thus is useful as an indicator of oxidative damage. Cardiac arrest significantly decreased aconitase activity ( Figure 7B ). Compared with placebo (14.8Ϯ8.4 mU/mg protein), nitrite therapy attenuated this loss of aconitase function (61.6Ϯ11.4 mU/mg protein; Pϭ0.05).
Discussion
We examined the effects of nitrite repletion on mitochondrial function, reperfusion ROS generation, organ function, and survival in a 12-minute mouse cardiac arrest model. Cardiac arrest results in systemic nitrite depletion, and low-dose nitrite replacement (therapy with 50 nmol) at CPR initiation restores these levels to near baseline and increases cardiac S-nitrosothiols. Therapeutic nitrite repletion and S-nitrosation in heart are associated with transient, reversible inhibition of complex I, reducing mitochondrial reperfusion, ROS generation, and oxidative injury. Nitrite improved pulmonary gas exchange, cardiac contractility, and survival with a suggestion of neuroprotection.
Moderate NO reperfusion therapy is known to be protective, 29 but NO formation is limited by the dependence of NO synthase on oxygen and reduced substrates. 30 Nitrite acts as a reservoir for NO during ischemia, and nitrite reduction generates NO through NOS-independent pathways. 6, 31, 32 We demonstrate that global ischemia depletes nitrite systemically, reducing its availability to act as a reperfusion NO source. This profound depletion with brief global ischemia was surprising but not unprecedented 13 and explains why our nitrite dose did not achieve the "optimal" plasma levels (11.9 mol/L) noted after focal ischemia. 8 Nitrite repletion early in reperfusion provides an NOS-independent source of NO to ischemic tissues.
Mitochondrial complexes I and III are major sources of pathological reperfusion ROS, 33 and transient, reversible inhibition of complex I has been proposed as a mechanism to achieve cardioprotection. 34 -36 The protective effects of complex I inhibition have been described for nitrite, 23 S-nitrosothiol donors, 28 and amobarbital 34 and observed during classic ischemic preconditioning. 25 Complex I has numerous cysteine residues available for S-nitrosation with resultant inhibition of electron flow. 37, 38 Nadtochiy and colleagues 28 S-nitrosated complex I in cardiomyocytes and isolated heart using S-nitroso-2-mercaptopropionyl glycine with an associated reduction in ROS production and improved cardiac contractility after ischemia/reperfusion. Similar to our findings, these authors noted reversal of S-nitrosation and complex I inhibition 30 minutes after ischemia. Shiva and colleagues 23 provided the first evidence that nitrite S-nitrosates complex I and reduces ROS production in liver mitochondria after in vitro ischemia/reperfusion, although inhibition persisted for 5 hours and was bypassed via complex II. Sun and colleagues 25 have shown complex I to be one of several proteins S-nitrosated in cardioprotective ischemic preconditioning.
Nitrite therapy is complex I specific on the basis of the lack of effects with succinate. Complex I efficiency is unaffected; therefore, this is not due to complex I damage. Complex I inhibition is reversible on the bass of restored oxygen, NADH consumption, and ATP generation by 60 minutes. The increase in complex I oxygen consumption with placebo in the absence of increased NADH oxidation implies pathological oxygen consumption to form ROS rather than ATP, which is prevented with nitrite. On the basis of our ROS and aconitase data, nitrite is an antioxidant. This mechanism complements prior observations of reduced tissue nitrotyrosine staining, 9, 39 lipid peroxidation, 9 and superoxide production 9 with nitrite therapy.
The poor prognosis of cardiac arrest is driven primarily by brain and heart injury. 15 Except for hypothermia, no beneficial postresuscitation therapies have emerged since the description of CPR Ϸ50 years ago. Present postresuscitation care is largely supportive. 15 The role of nitrite as a novel therapeutic agent would be of great importance in this setting.
Human myocardial dysfunction (stunning) is common in cardiac arrest, 40, 41 is ultimately reversible, 42 and is strongly associated with mortality 40, 41 The molecular mechanisms of myocardial stunning after cardiac arrest remain unknown, but loss of excitation-contraction coupling is believed to result from ROS injury and calcium-mediated proteolysis. 43 Nitrite, by reducing ROS, may mitigate stunning, similar to other antioxidants. 44 The reduction in myocardial dysfunction likely explains the 50% relative survival advantage we noted. Further work is needed to characterize the effects of nitrite on brain injury, but our results are encouraging. Nitrite therapy effects on mitochondrial oxidative burst and injury. A, ROS generation was measured as mitochondrial peroxide production using the Amplex Red assay. Cardiac arrest increased ROS at 5 and 15 minutes, which resolved by 60 minutes. Compared with placebo, nitrite reduced ROS production 5 minutes (nϭ7) after CPR with a similar trend at 15 minutes (nϭ4). B, Cardiac arrest resulted in a significant loss of heart aconitase activity, which improves with nitrite therapy. Inset, Sample trace from each group. Values denoted as meanϮSEM analyzed by paired t test (ROS) or ANOVA (aconitase). *PϽ0.01, †Pϭ0.071, and PϽ0.01, sham (nϭ11) vs placebo (nϭ8); #Pϭ0.05, nitrite (nϭ8) vs placebo.
We designed a mouse model of cardiac arrest with prolonged asystole to study the effects of nitrite on heart and brain injury after resuscitation. Our model uses hyperkalemia to induce arrest, limiting its clinical relevance and potentially causing artifacts that may be organ protective (eg, cardioplegia) or injurious (endothelial damage perhaps causing RV dysfunction). In the context of these limitations, we demonstrate improvements in gas exchange, heart and brain function, and survival. We demonstrate that nitrite transiently inhibits complex I, resulting in an antioxidant effect. The ease in delivering intravenous nitrite, its established human safety, 14, 31 and its reproducible cytoprotective effects in multiple organs and species 6 all suggest that nitrite represents a promising postresuscitation therapy after cardiac arrest.
